Literature DB >> 22441720

Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.

A E Raptis1, D Bacharaki, M Mazioti, K P Marathias, K P Markakis, S A Raptis, G D Dimitriadis, D V Vlahakos.   

Abstract

Therapy with either angiotensin converting enzyme inhibitors and angiotensin receptor blockers (ACEI/ARB) or thiazolidinediones (TZD) is associated with dose-dependent decrements in hematocrit and hemoglobin levels. We aimed to investigate the impact of the coadministration of TZD and ACEI/ARB on hematocrit and hemoglobin values in uncomplicated patients with type 2 diabetes mellitus and normal serum creatinine.Data from patients with type 2 diabetes currently followed, were reviewed and patients treated with ACEI/ARB and/or TZD were identified. For the purpose of this study the following 4 groups of 30 stable non-anemic diabetic patients each matched for age, gender, and BMI were formed. Group ACEI/ARB included patients on ACEI/ARB without TZD, group TZD included patients on TZD and antihypertensive agents other than ACEI/ARB, group ACEI/ARB/TZD consisted of patients on combined therapy with ACEI/ARB and TZD and the control group C included patients never exposed to ACEI/ARB or TZD. Clinical and laboratory data were collected prior to initiation of treatment and after 6 months.Neither hematocrit nor hemoglobin showed any significant change from baseline at the end of the study in group C. In both group ACEI/ARB and group TZD a small, but statistically significant reduction in hematocrit (~ 1% point) and hemoglobin levels (~ 0.3 g/dl) was seen. A greater statistically and clinically important reduction in hematocrit (~ 3% points) and hemoglobin (~ 1 g/dl) levels was observed in group ACEI/ARB/TZD. Furthermore, incident anemia at the end reached 7% in group TZD and 23% in group ACEI/ARB/TZD.Coadministration of RAS inhibitors and PPAR-γ agonists should be considered in the differential diagnosis of hematocrit lowering and anemia in uncomplicated type 2 diabetic patients with normal serum creatinine. Further studies are required to clarify the mechanism(s), the cardiovascular consequences and the cost utility of anemia workup in such patients. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22441720     DOI: 10.1055/s-0032-1306286

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

1.  Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy.

Authors:  James F Crismale; Valérie Martel-Laferrière; Kian Bichoupan; Emily Schonfeld; Alexis Pappas; Christina Wyatt; Joseph A Odin; Lawrence U Liu; Thomas D Schiano; Ponni V Perumalswami; Meena Bansal; Douglas T Dieterich; Andrea D Branch
Journal:  Liver Int       Date:  2013-10-25       Impact factor: 5.828

Review 2.  Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy.

Authors:  M Pappa; E Dounousi; A Duni; K Katopodis
Journal:  Int Urol Nephrol       Date:  2015-05-28       Impact factor: 2.370

3.  Association of Age and Anemia With Adiponectin Serum Levels in Normal-Weight Japanese Women.

Authors:  Mari Honda; Ayaka Tsuboi; Satomi Minato; Kaori Kitaoka; Mika Takeuchi; Megumu Yano; Miki Kurata; Bin Wu; Tsutomu Kazumi; Keisuke Fukuo
Journal:  J Clin Med Res       Date:  2019-04-14

4.  Discontinuation of the renin-angiotensin system inhibitors improves erythropoiesis in patients with lower-risk myelodysplastic syndromes.

Authors:  George Pavlidis; Sotirios G Papageorgiou; Efthimia Bazani; Anthi Bouchla; Eirini Glezou; Konstantinos Gkontopoulos; Thomas Thomopoulos; Vasiliki Pappa; Demetrios V Vlahakos
Journal:  Ther Adv Hematol       Date:  2021-01-13

Review 5.  Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma.

Authors:  Patricia Corrales; Adriana Izquierdo-Lahuerta; Gema Medina-Gómez
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

Review 6.  PPARγ and Its Agonists in Chronic Kidney Disease.

Authors:  Yuhua Ma; Manman Shi; Yuxin Wang; Jian Liu
Journal:  Int J Nephrol       Date:  2020-02-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.